Inhalation Tuesday, April 24, 2018
Skip Navigation LinksHome) Custom Webinar - Capsugel/Lovelace - 5/25/2017
Inhalation is the only technical publication devoted exclusively to readers involved in development and production of pulmonary or nasal delivered pharmaceuticals.

        Capsugel is a global leader in delivering high-                       Lovelace Biomedical is a not-for-profit
        quality, innovative dosage forms and solutions                      contract research organization with a rich
           to healthcare companies around the world.                          history of helping its pharmaceutical and
                                                                                                        biotechnology partners achieve great things.


Engineered Particle Platform for Rapid
Assessment of Inhaled Formulations

  Thursday, May 25, 2017

Time:  10:30 AM – 11:30 AM ET

Presented by:  Devon Dubose, Senior Manager Inhalation Product Development, Capsugel Bend
                            Philip Kuehl, Scientist, Director—Scientific Core Laboratories, Lovelace Respiratory Research Institute

Moderated by:  TBD

Webinar Cost:  FREE

Webinar Details:  An increasing number of therapies are targeting lung delivery for treatment of selected disease states. These include novel targets for improved treatment of asthma and COPD but also for localized infection and orphan disease states. The active pharmaceutical ingredients (API) being developed for these disease states span a broad range of physical/chemical properties and range in classification from small molecules to more complex milli-molecules to biomolecules ranging from siRNA to mAbs. Many of these new actives—due to poor crystallinity, poor stability, or narrow therapeutic index, are unsuitable for traditional inhalation processes and formulations.

Capsugel has developed a spray-dried engineered particle platform for the delivery of API with a broad range of physical properties to the lung. These engineered formulations allow for the manufacture of high fine particle fraction (FPF) formulations using a gentle process addressing key issues described above. This in turn allows for rapid formulation development and assessment. These formulations have been evaluated by Lovelace Respiratory Institute in a variety of select animal models including models for bronchoconstriction and fibrosis.

Case studies describing optimization of spray drying processes for manufacture of engineered particles will be shown in this presentation. In vitro characterization of these materials will be presented along with in vivo evaluation of the materials.

Presenter Information:  Devon DuBose is Technical Group Lead at Capsugel Bend. His responsibilities include leading multiple teams focused on the development of early phase drug candidates and technology transfer into Capsugel Bend’s cGMP facility for clinical manufacture. His technical focus during his time at Bend has been on spray drying formulation and process development for oral and inhalation drug products. Mr. DuBose has been with Capsugel/Bend Research since 2007. He graduated with a B.S. in chemical engineering from Oregon State University and is a registered professional engineer in the State of Oregon.

Philip Kuehl, Ph.D., is a scientist and head of the Scientific Core Laboratories at Lovelace Biomedical. The Scientific Core Laboratories are responsible for the formulation, chemistry, bioanalysis, aerosol engineering solutions, microbial analysis and telemetry systems. Dr. Kuehl is an expert in formulation by all routes, and is renowned for his contributions to pulmonary formulation and respiratory drug development. He has over 45 publications in drug development and formulation, is a managing member of the Inhalation and Nasal Technology Focus Group and ad hoc reviewer of numerous journals. Dr. Kuehl received his B.A. in biochemistry from Hamline University in St. Paul, Minnesota and a Ph.D. in pharmaceutical sciences (minor in analytical chemistry) from the University of Arizona. Dr. Kuehl joined Lovelace in 2007.

Can’t attend?  If you register for a webinar but can't attend the live event, an archived version will be accessible online for 30 days once it concludes. This allows you to view the entire webinar presentation and Q&A session at a time most convenient to your schedule.

      Copyright 2018, CSC Publishing Inc. ALL Rights Reserved * Privacy policy